BETRF (BetterLife Pharma) Cyclically Adjusted FCF per Share: $-0.16 (As of Apr. 2026)


BETRF BetterLife Pharma Inc BETRF
27 GF Score
Price $0.14
! 2 Warning Signs
View Full Analysis

What is BetterLife Pharma Cyclically Adjusted FCF per Share?

BetterLife Pharma BETRF +3.05% 27 Cyclically Adjusted FCF per Share is $-0.16 as of Apr. 2026. GuruFocus rates BETRF with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BetterLife Pharma's adjusted free cash flow per share for the three months ended in Apr. 2026 was $-0.001. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.16 for the trailing ten years ended in Apr. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BetterLife Pharma was -1.60% per year. The lowest was -26.00% per year. And the median was -5.65% per year.

As of today (2026-07-08), BetterLife Pharma's current stock price is $0.135. BetterLife Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Apr. 2026 was $-0.16. BetterLife Pharma's Cyclically Adjusted Price-to-FCF of today is .


BetterLife Pharma  (OTCPK:BETRF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BetterLife Pharma Cyclically Adjusted FCF per Share Related Terms


BetterLife Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BetterLife Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BetterLife Pharma Cyclically Adjusted FCF per Share Chart

BetterLife Pharma Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.15 -0.12 0.00 -0.16

BetterLife Pharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.17 0.00 -0.16 -0.16

BETRF vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BetterLife Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Cyclically Adjusted Price-to-FCF falls into.


BETRF
27GF Score
BetterLife Pharma Inc BETRF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BetterLife Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BetterLife Pharma's adjusted Free Cash Flow per Share data for the three months ended in Apr. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.001/132.7364*132.7364
=-0.001

Current CPI (Apr. 2026) = 132.7364.

BetterLife Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201607 -0.005 101.844 -0.007
201610 -0.020 102.002 -0.026
201701 -0.012 102.318 -0.016
201704 -0.009 103.029 -0.012
201707 -0.004 103.029 -0.005
201710 -0.012 103.424 -0.015
201801 -0.027 104.056 -0.034
201804 -0.220 105.320 -0.277
201807 -0.081 106.110 -0.101
201810 -0.080 105.952 -0.100
201901 -0.035 105.557 -0.044
201904 -0.032 107.453 -0.040
201907 -0.213 108.243 -0.261
201910 -0.068 107.927 -0.084
202001 -0.068 108.085 -0.084
202004 -0.056 107.216 -0.069
202007 -0.033 108.401 -0.040
202010 -0.063 108.638 -0.077
202101 -0.041 109.192 -0.050
202104 -0.042 110.851 -0.050
202107 -0.044 112.431 -0.052
202110 -0.020 113.695 -0.023
202201 -0.018 114.801 -0.021
202204 -0.004 118.357 -0.004
202207 -0.003 120.964 -0.003
202210 -0.005 121.517 -0.005
202301 -0.001 121.596 -0.001
202304 -0.010 123.571 -0.011
202307 -0.003 124.914 -0.003
202310 -0.003 125.310 -0.003
202401 -0.002 125.072 -0.002
202404 -0.005 126.890 -0.005
202407 -0.006 128.075 -0.006
202410 -0.001 127.838 -0.001
202501 0.000 127.443 0.000
202504 0.000 129.102 0.000
202507 -0.001 130.290 -0.001
202510 0.000 130.603 0.000
202601 -0.002 130.366 -0.002
202604 -0.001 132.736 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.16 mean?
BetterLife Pharma (BETRF) has a Cyclically Adjusted FCF per Share of $-0.16 as of Apr. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BetterLife Pharma and its competitors.
Is BetterLife Pharma's Cyclically Adjusted FCF per Share too high?
BetterLife Pharma's current Cyclically Adjusted FCF per Share is $-0.16. Overall, BetterLife Pharma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
BetterLife Pharma's Cyclically Adjusted FCF per Share of $-0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BetterLife Pharma and its competitors. BetterLife Pharma's current Cyclically Adjusted FCF per Share is $-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current Cyclically Adjusted FCF per Share of $-0.16. The current Cyclically Adjusted FCF per Share is $-0.16. BetterLife Pharma's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current Cyclically Adjusted FCF per Share is $-0.16 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BetterLife Pharma Business Description

Other Exchanges NPAU:GermanyBETR:Canada
Address 1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
27GF Score

Get the complete analysis for BETRF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price